# Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes

> **NCT00378508** · PHASE2 · COMPLETED · sponsor: **Yale University** · enrollment: 63 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** mAb hOKT3gamma1(Ala-Ala), Teplizumab
- **DRUG:** Placebo Arm

## Key facts

- **NCT ID:** NCT00378508
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2011-08
- **Final completion:** 2013-08
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2021-08-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00378508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00378508, "Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00378508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*